TrialThe Lancet. Neurology2016

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Emily J Henderson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.